Downregulation of osteopontin is associated with fluoxetine amelioration of monocrotaline-induced pulmonary inflammation and vascular remodelling

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 6, 2011, Pages 365-372

  Wang, Yun ^a   Han, Dan Dan ^a   Wang, Han Ming ^a   Liu, Ming ^a   Zhang, Xin Hua ^a   Wang, Huai Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Osteopontin; Pulmonary arterial hypertension; Remodelling; Selective serotonin reuptake inhibitor; Serotonin transporter

Indexed keywords

FLUOXETINE; GELATINASE A; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCROTALINE; OSTEOPONTIN; SEROTONIN TRANSPORTER; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; MALE; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLUOXETINE; INFLAMMATION; LUNG; LUNG DISEASES; MONOCROTALINE; OSTEOPONTIN; PULMONARY ARTERY; PULMONARY CIRCULATION; RATS; RATS, INBRED WF; SEROTONIN UPTAKE INHIBITORS;

EID: 79956290843     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05516.x     Document Type: Article

References (43)

1. Schäfer S, Ellinghaus P, Janssen W et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodeling. Cardiovasc. Res. 2009; 82: 30-9.
2. Weir EK, Hong ZG, Varghese A. The serotonin transporter a vehicle to elucidate pulmonary hypertension? Circ. Res. 2004; 94: 1152-4.
3. Humbert M, Montani D, Perros F, Dorfmüller P, Adnot S, Eddahibi S. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul. Pharmacol. 2008; 49: 113-8.
4. Uenoyama M, Ogata S, Nakanishi K et al. Osteopontin expression in normal and hypobaric hypoxia-exposed rats. Acta Physiol. 2008; 193: 291-301.
5. Butler WT. The nature and significance of osteopontin. Connect. Tissue Res. 1989; 23: 123-36.
6. Takahashi F, Kumasaka T, Nagaoka T et al. Osteopontin expression in pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. Pathol. Int. 2009; 59: 752-6.
7. Ueno T, Miyazaki E, Ando M, Nureki SI, Kumamoto T. Osteopontin levels are elevated in patients with eosinophilic pneumonia. Respirology 2010; 15: 1111-21.
8. van der Windt GJ, Hoogerwerf JJ, de Vos AF, Florquin S, van der Poll T. Osteopontin promotes host defense during Klebsiella pneumoniae-induced pneumonia. Eur. Respir. J. 2010; 36: 1337-45.
9. Scatena M, Liaw L, Giachelli CM. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 2302-9.
10. Amanda-Lund S, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J. Cell Commun. Signal. 2009; 3: 311-22.
11. Cao Z, Dai J, Fan K et al. A novel functional motif of osteopontin for human lymphocyte migration and survival. Mol. Immunol. 2008; 45: 3683-92.
12. Kurokawa M, Konno S, Matsukura S et al. Effects of corticosteroids on osteopontin expression in a murine model of allergic asthma. Int. Arch. Allergy Immunol. 2009; 149(Suppl.): S7-13.
13. Zheng WX, Li RS, Pan H et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum. 2009; 60: 1957-65.
14. Okamoto H. Osteopontin and cardiovascular system. Mol. Cell. Biochem. 2007; 300: 1-7.
15. Gürsoy G, Acar Y, Alagöz S. Osteopontin: A multifunctional molecule. J. Med. Med. Sci. 2010; 1: 55-60.
16. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr. Protein Pept. Sci. 2002; 3: 409-21.
17. Buback F, Renkl AC, Schulz G, Weiss JM. Osteopontin and the skin. Multiple emerging roles in cutaneous biology and pathology. Exp. Dermatol. 2009; 18: 750-9.
18. Liu H, Chen A, Guo F, Yuan L. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett. 2010; 295: 27-37.
19. Morrell NW, Adnot S, Archer SL et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 54(Suppl.): S20-31.
20. Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 2001; 108: 1141-50.
21. Dizeyi N, Hedlund P, Bjartell A, Tinzl M, Austild-Taskén K, Abrahamsson PA. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol. Oncol. 2009; 27: Epub 20 November 2009; doi:.
22. Singh M, Foster CR, Dalal S, Singh K. Osteopontin: Role in extracellular matrix deposition and myocardial remodeling post-MI. J. Mol. Cell. Cardiol. 2010; 48: 538-43.
23. Zhai FG, Zhang XH, Wang HL. Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: Potential roles of induction of apoptosis and upregulation of kv1.5 channels in rats. Clin. Exp. Pharmacol. Physiol. 2009; 36: 850-6.
24. Zhang XH, Chen L, Wang HL, Gao J. Methodological study of determination of rat pulmonary artery pressure. J. Chin. Med. Univ. 2004; 33: 388-9 (in Chinese).
25. Li XQ, Hong Y, Wang Y, Zhang XH, Wang HL. Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. Clin. Exp. Pharmacol. Physiol. 2006; 33: 1047-51.
26. Xu G, Nie H, Li N et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J. Clin. Invest. 2005; 115: 1060-7.
27. Maier R, Weger M, Haller-Schober EM et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol. Vis. 2008; 14: 637-43.
28. Gouwy M, Struyf S, Proost P, Damme JV. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev. 2005; 16: 561-80.
29. Chen YF, Feng JA, Li P, Xing DQ, Ambalavanan N, Oparil S. Atrial natriuretic peptide-dependent modulation of hypoxia-induced pulmonary vascular remodeling. Life Sci. 2006; 79: 1357-65.
30. Krishnamurthy P, Peterson JT, Subramanian V, Singh M, Singh K. Inhibition of matrix metalloproteinases improves left ventricular function in mice lacking osteopontin after myocardial infarction. Mol. Cell. Biochem. 2009; 322: 53-62.
31. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 1994; 74: 214-24.
32. Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB, Mukherjee BB. Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J. Biol. Chem. 2000; 275: 969-76.
33. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor- kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 2001; 276: 44926-35.
34. Xie Z, Singh M, Siwik DA, Joyner WL, Singh K. Osteopontin inhibits interleukin-1beta-stimulated increases in matrix metalloproteinase activity in adult rat cardiac fibroblasts: Role of protein kinase C-zeta. J. Biol. Chem. 2003; 278: 48546-52.
35. Giannelli G, Bergamini C, Marinosci F et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int. J. Cancer 2002; 97: 425-31.
36. Song D, Wang HL, Wang S, Zhang XH. 5-Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells is extracellular signal-regulated kinase pathway dependent. Acta Pharmacol. Sin. 2005; 26: 563-7.
37. Isoda K, Nishikawa K, Kamezawa Y et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ. Res. 2002; 91: 77-82.
38. 7 receptor. Blood 2007; 109: 3139-46.
39. Li P, Oparil S, Feng WG, Chen YF. Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. J. Appl. Physiol. 2004; 97: 1550-8.
40. Hoshikawa Y, Matsuda Y, Sakuma M, Kondo T. Potential therapeutic target for pulmonary arterial hypertension: Osteopontin. Nippon Rinsho 2008; 66: 2097-101 (in Japanese with an English abstract).
41. Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells potentiation by high glucose. Diabetes 2001; 50: 1482-90.
42. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J. Cell. Biochem. 2007; 102: 912-24.
43. Randall PA, Heitzman ER, Bull MJ et al. Pulmonary arterial hypertension: A contemporary review. Radiographics 1989; 9: 905-27.